Cancer Genetics, Inc.
Cancer Genetics, Inc., a leading player in the oncology-focused genetic testing industry, is headquartered in the United States. Founded in 2000, the company has established itself as a pioneer in providing advanced genomic testing services that aid in the diagnosis and management of cancer. With a strong presence across major operational regions in North America and Europe, Cancer Genetics, Inc. offers a comprehensive suite of products, including molecular diagnostics and genomic profiling. What sets Cancer Genetics apart is its commitment to precision medicine, utilising cutting-edge technology to deliver tailored insights for oncologists and patients alike. The company has achieved significant milestones, including partnerships with prominent healthcare institutions, solidifying its market position as a trusted provider of cancer-related genetic information. Through its innovative approach, Cancer Genetics, Inc. continues to make strides in improving patient outcomes in the fight against cancer.
DitchCarbon Score
How does Cancer Genetics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cancer Genetics, Inc.'s score of 19 is lower than 71% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Cancer Genetics, Inc.'s reported carbon emissions
Cancer Genetics, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. As a merged entity, it does not report any absolute emissions figures, including Scope 1, 2, or 3 emissions, nor does it have documented reduction targets or climate pledges. The absence of emissions data suggests that Cancer Genetics, Inc. may be in the early stages of developing its climate commitments or may rely on broader corporate family initiatives for guidance. As such, the company has not yet established specific reduction targets or initiatives that are publicly documented. Given the lack of specific emissions data and reduction initiatives, it is essential for Cancer Genetics, Inc. to consider setting measurable climate goals and participating in industry-standard frameworks to enhance its sustainability profile and align with global climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | |
|---|---|---|
| Scope 1 | 533,000,000 | 000,000 |
| Scope 2 | - | 000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Cancer Genetics, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
